Compare Davita Inc (DVA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Northrop Grumman Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Northrop Grumman Corporation trades at $485.55 (market cap $67.26B). The key difference: Northrop Grumman Corporation is far larger — about 6× Davita Inc's market cap, and Northrop Grumman Corporation pays a 2.09% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Northrop Grumman Corporation for 81 Days on average.
| DVA | NOC | |
|---|---|---|
Market Cap | $11.28B | $67.26B |
Volume | 650,294 | 711,592 |
Sector | Health | Industrials |
52-Week High | $240.96 | $768.02 |
52-Week Low | $103.87 | $473.46 |
Typical Hold Time | 113 Days | 81 Days |
Enterprise Value | $24.00B | $81.24B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Northrop Grumman (NOC) trades at $484.48, up 0.28% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 12.6%. Recent news highlights the loss of a $20B Navy fighter contract to Boeing, creating near-term headwinds. Technical indicators show oversold conditions with RSI at 16.17, while the stock trades below key resistance at $484.
NOC presents a compelling value opportunity with a 15.05 P/E ratio and 26.96% ROE, supported by a 54% analyst buy rating and $615.75 price target. Risks include competitive contract losses and defense budget uncertainties, but the company's $104.7B backlog and dividend growth provide stability. The current technical weakness may offer entry points for long-term investors seeking defense exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
